Loading...
Disclaimer: Informational only — not medical advice. AI hypotheses are not clinically validated. Medic Oath is for informational and educational purposes only — not medical advice. AI-generated hypotheses have not been clinically validated. Always consult a qualified healthcare professional. Privacy · Terms
Timestamped drug→disease repurposing candidates from the learned ranker (DWPC + logistic regression). Append-only — a public, pre-registered track record.
These are ranked model predictions, not validated cures. A high score means the graph structure resembles known treatments — it does not establish efficacy. Real-world-evidence causal validation is a separate, later signal. Never start, stop, or change a medicine based on these predictions — they are a research signal, not medical advice; consult a clinician.
Prospective track record
7 prediction(s) have entered NEW trials registered after the prediction — tracking toward confirmation.
Only prospective tiers (a trial that began after the prediction) count as forward hits. "Concordant" means a trial already existed at prediction time — baseline plausibility, not a prediction win.
| Drug | Disease | Score | Genetic | Trials | Predicted | Status |
|---|---|---|---|---|---|---|
| Cintredekin Besudotox | allergic rhinitis | 1.000 | 🧬 0.84 | — | 2026-10-05 | pending |
| CAT-213 | allergic rhinitis | 1.000 | — | — | 2026-10-05 | pending |
| Tasonermin | allergic rhinitis | 1.000 | — | — | 2026-10-05 | pending |
| Vercirnon | allergic rhinitis | 1.000 | — | — | 2026-10-05 | pending |
| ROX-888 | allergic rhinitis | 1.000 | — | 2 pre-existing | 2026-10-05 | pending |
| Ethanesulfonic acid | allergic rhinitis | 1.000 | — | — | 2026-10-05 | pending |
| Secukinumab | allergic rhinitis | 1.000 | — | — | 2026-10-05 | pending |
| Ixekizumab | allergic rhinitis | 1.000 | — | — | 2026-10-05 | pending |
| Omalizumab | allergic rhinitis | 1.000 | — | 12 pre-existing | 2026-10-05 | pending |
| Omalizumab | atopic dermatitis | 1.000 | — | 9 pre-existing | 2026-10-05 | pending |
| Pramlintide | migraine | 1.000 | — | 2 pre-existing | 2026-10-05 | pending |
| Guanosine-5'-Diphosphate | metabolic syndrome x | 1.000 | — | — | 2026-10-05 | pending |
| Arginineamide | thymus cancer | 1.000 | — | — | 2026-10-05 | pending |
| 1D09C3 | allergic rhinitis | 1.000 | 🧬 0.38 | — | 2026-10-05 | pending |
| Lebrikizumab | allergic rhinitis | 1.000 | 🧬 0.84 | 1 pre-existing | 2026-10-05 | pending |
| Coccidioides immitis spherule | allergic rhinitis | 1.000 | 🧬 0.38 | — | 2026-10-05 | pending |
| 1-{[(3R)-3-methyl-4-({4-[(1S)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]phenyl}sulfonyl)piperazin-1-yl]methyl}cyclopropanecarboxamide | metabolic syndrome x | 0.979 | — | — | 2026-10-05 | pending |
| 2-(6-{[(3-chloro-2-methylphenyl)sulfonyl]amino}pyridin-2-yl)-N,N-diethylacetamide | metabolic syndrome x | 0.979 | — | — | 2026-10-05 | pending |
| 2-(2-CHLORO-4-FLUOROPHENOXY)-2-METHYL-N-[(1R,2S,3S,5S,7S)-5-(METHYLSULFONYL)-2-ADAMANTYL]PROPANAMIDE | metabolic syndrome x | 0.979 | — | — | 2026-10-05 | pending |
| (1S,3R,4S,5S,7S)-4-{[2-(4-METHOXYPHENOXY)-2-METHYLPROPANOYL]AMINO}ADAMANTANE-1-CARBOXAMIDE | metabolic syndrome x | 0.979 | — | — | 2026-10-05 | pending |
| (2R)-1-[(4-tert-butylphenyl)sulfonyl]-2-methyl-4-(4-nitrophenyl)piperazine | metabolic syndrome x | 0.979 | — | — | 2026-10-05 | pending |
| N-{1-[(1-carbamoylcyclopropyl)methyl]piperidin-4-yl}-N-cyclopropyl-4-[(1S)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]benzamide | metabolic syndrome x | 0.979 | — | — | 2026-10-05 | pending |
| Carbenoxolone | metabolic syndrome x | 0.979 | — | — | 2026-10-05 | pending |
| N-cyclopropyl-N-(trans-4-pyridin-3-ylcyclohexyl)-4-[(1S)-2,2,2-trifluoro-1-hydroxy-1-methylethyl]benzamide | metabolic syndrome x | 0.979 | — | — | 2026-10-05 | pending |
| (5S)-2-{[(1S)-1-(2-fluorophenyl)ethyl]amino}-5-methyl-5-(trifluoromethyl)-1,3-thiazol-4(5H)-one | metabolic syndrome x | 0.979 | — | — | 2026-10-05 | pending |
| (5S)-2-(Cyclooctylamino)-5-methyl-5-propyl-1,3-thiazol-4(5H)-one | metabolic syndrome x | 0.979 | — | — | 2026-10-05 | pending |
| (5R)-2-[(2-Fluorophenyl)amino]-5-isopropyl-1,3-thiazol-4(5H)-one | metabolic syndrome x | 0.979 | — | — | 2026-10-05 | pending |
| (5S)-2-{[(1S)-1-(4-Fluorophenyl)ethyl]amino}-5-(2-hydroxy-2-propanyl)-5-methyl-1,3-thiazol-4(5H)-one | metabolic syndrome x | 0.979 | — | — | 2026-10-05 | pending |
| (3,3-dimethylpiperidin-1-yl)(6-(3-fluoro-4-methylphenyl)pyridin-2-yl)methanone | metabolic syndrome x | 0.979 | — | — | 2026-10-05 | pending |
| INCB13739 | metabolic syndrome x | 0.979 | — | — | 2026-10-05 | pending |
| Benralizumab | allergic rhinitis | 0.906 | — | — | 2026-10-05 | pending |
| Fremanezumab | thyroid cancer | 0.897 | — | — | 2026-10-05 | pending |
| Eptinezumab | thyroid cancer | 0.897 | — | — | 2026-10-05 | pending |
| Galcanezumab | thyroid cancer | 0.897 | — | — | 2026-10-05 | pending |
| Iodine | hypothyroidism | 0.892 | 🧬 0.95 | 25 pre-existing | 2026-10-05 | pending |
| L-alanyl-N-[(1S,2R)-1-benzyl-2-hydroxypropyl]-L-alaninamide | atopic dermatitis | 0.892 | — | — | 2026-10-05 | pending |
| amifostine | paget's disease of bone | 0.858 | — | — | 2026-10-05 | pending |
| Protirelin | hypothyroidism | 0.822 | 🧬 0.84 | 2 pre-existing | 2026-10-05 | pending |
| Atezolizumab | allergic rhinitis | 0.803 | — | — | 2026-10-05 | pending |
| Durvalumab | allergic rhinitis | 0.803 | — | — | 2026-10-05 | pending |
| Avelumab | allergic rhinitis | 0.803 | — | — | 2026-10-05 | pending |
| guanidine | epilepsy syndrome | 0.790 | 🧬 0.96 | — | 2026-10-05 | pending |
| l-cystine | nephrolithiasis | 0.766 | 🧬 0.43 | 3 pre-existing | 2026-10-05 | pending |
| Cystine | nephrolithiasis | 0.766 | 🧬 0.43 | 3 pre-existing | 2026-10-05 | pending |
| Insulin pork | allergic rhinitis | 0.764 | 🧬 0.28 | — | 2026-10-05 | pending |
| Foreskin fibroblast (neonatal) | allergic rhinitis | 0.754 | — | — | 2026-10-05 | pending |
| pranlukast | allergic rhinitis | 0.730 | 🧬 0.87 | 3 pre-existing | 2026-10-05 | pending |
| Pentaglyme | allergic rhinitis | 0.729 | — | — | 2026-10-05 | pending |
| dalfampridine | epilepsy syndrome | 0.706 | 🧬 0.96 | — | 2026-10-05 | pending |
| Cerliponase alfa | dilated cardiomyopathy | 0.702 | — | — | 2026-10-05 | pending |
| [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID | type 2 diabetes mellitus | 0.701 | 🧬 0.77 | — | 2026-10-05 | pending |
| Omalizumab | asthma | 0.695 | — | 25 pre-existing | 2026-10-05 | pending |
| N-Formylmethionine | crohn's disease | 0.692 | — | — | 2026-10-05 | pending |
| Ammonia | gestational diabetes | 0.692 | — | — | 2026-10-05 | pending |
| Telcagepant | thyroid cancer | 0.682 | — | — | 2026-10-05 | pending |
| Artenimol | rheumatoid arthritis | 0.681 | 🧬 0.58 | — | 2026-10-05 | pending |
| XmAb 2513 | lymphatic system cancer | 0.652 | — | 1 pre-existing | 2026-10-05 | pending |
| biotin | dilated cardiomyopathy | 0.645 | — | — | 2026-10-05 | pending |
| Sodium phosphate, dibasic | nephrolithiasis | 0.644 | 🧬 0.72 | 1 pre-existing | 2026-10-05 | pending |
| Sodium phosphate, monobasic, unspecified form | nephrolithiasis | 0.644 | 🧬 0.72 | — | 2026-10-05 | pending |
| Sodium phosphate, monobasic | nephrolithiasis | 0.644 | 🧬 0.72 | — | 2026-10-05 | pending |
| Phenethyl Isothiocyanate | barrett's esophagus | 0.609 | — | — | 2026-10-05 | pending |
| 2-ACETAMIDO-2-DEOXY-BETA-D-GLUCOPYRANOSE(BETA1-4)-2-ACETAMIDO-1,6-ANHYDRO-3-O-[(R)-1-CARBOXYETHYL]-2-DEOXY-BETA-D-GLUCOPYRANOSE-L-ALANYL-GAMMA-D-GLUTAMYL-MESO-DIAMINOPIMELYL-D-ALANINE | epilepsy syndrome | 0.605 | — | — | 2026-10-05 | pending |
| Matairesinol | barrett's esophagus | 0.592 | — | — | 2026-10-05 | pending |
| Artenimol | colon cancer | 0.590 | — | 1 pre-existing | 2026-10-05 | pending |
| (2S)-2-(3-bromophenyl)-3-(5-chloro-2-hydroxyphenyl)-1,3-thiazolidin-4-one | ankylosing spondylitis | 0.590 | 🧬 0.44 | — | 2026-10-05 | pending |
| N-[2-(2-methyl-1H-indol-3-yl)ethyl]thiophene-2-carboxamide | ankylosing spondylitis | 0.590 | 🧬 0.44 | — | 2026-10-05 | pending |
| (3AR,6R,6AS)-6-((S)-((S)-CYCLOHEX-2-ENYL)(HYDROXY)METHYL)-6A-METHYL-4-OXO-HEXAHYDRO-2H-FURO[3,2-C]PYRROLE-6-CARBALDEHYDE | colon cancer | 0.575 | — | — | 2026-10-05 | pending |
| METHYL-PHOSPHONIC ACID MONO-(4-NITRO-PHENYL) ESTER | paget's disease of bone | 0.574 | — | — | 2026-10-05 | pending |
| N-Formylmethionine | psoriasis | 0.573 | — | — | 2026-10-05 | pending |
| Artenimol | breast cancer | 0.564 | 🧬 0.77 | — | 2026-10-05 | pending |
| Secretin human | type 2 diabetes mellitus | 0.561 | 🧬 0.84 | — | 2026-10-05 | pending |
| linaclotide | ulcerative colitis | 0.555 | — | 1 pre-existing | 2026-10-05 | pending |
| APD668 | crohn's disease | 0.554 | — | — | 2026-10-05 | pending |
| Farnesyl thiopyrophosphate | rheumatoid arthritis | 0.553 | — | — | 2026-10-05 | pending |
| Tiludronic acid | barrett's esophagus | 0.551 | — | — | 2026-10-05 | pending |
| Copper | lymphatic system cancer | 0.548 | — | 5 pre-existing | 2026-10-05 | pending |
| N-Formylmethionine | polycystic ovary syndrome | 0.546 | — | — | 2026-10-05 | pending |
| Artenimol | systemic scleroderma | 0.542 | — | — | 2026-10-05 | pending |
| Tiludronic acid | kidney cancer | 0.541 | — | — | 2026-10-05 | pending |
| Magnesium | nephrolithiasis | 0.538 | 🧬 0.54 | 5 pre-existing | 2026-10-05 | pending |
| Corticosterone | metabolic syndrome x | 0.531 | — | — | 2026-10-05 | pending |
| Lesinurad | gout | 0.529 | 🧬 0.94 | 14 pre-existing | 2026-10-05 | pending |
| Daclizumab | systemic lupus erythematosus | 0.522 | 🧬 0.69 | — | 2026-10-05 | pending |
| cholecalciferol | ocular cancer | 0.509 | — | 1 pre-existing | 2026-10-05 | pending |
| Human immunoglobulin G | systemic lupus erythematosus | 0.507 | 🧬 0.69 | 1 pre-existing | 2026-10-05 | pending |
| Technetium Tc-99m tilmanocept | type 2 diabetes mellitus | 0.502 | — | — | 2026-10-05 | pending |
| Artenimol | malaria | 0.496 | — | 17 pre-existing | 2026-10-05 | pending |
| E-2012 | alzheimer's disease | 0.494 | — | — | 2026-10-05 | pending |
| TRC093 | focal segmental glomerulosclerosis | 0.492 | 🧬 0.84 | — | 2026-10-05 | pending |
| Phenethyl Isothiocyanate | crohn's disease | 0.487 | 🧬 0.47 | — | 2026-10-05 | pending |
| alpha-D-mannose 6-phosphate | dilated cardiomyopathy | 0.484 | — | — | 2026-10-05 | pending |
| Romosozumab | osteoporosis | 0.481 | 🧬 0.19 | ↗ prospective · P4 | 2026-10-05 | pending |
| 3,5-Diiodotyrosine | hypothyroidism | 0.480 | 🧬 0.81 | — | 2026-10-05 | pending |
| N-Formylmethionine | ankylosing spondylitis | 0.474 | — | — | 2026-10-05 | pending |
| Elotuzumab | psoriasis | 0.472 | — | — | 2026-10-05 | pending |
| N-Formylmethionine | breast cancer | 0.452 | — | — | 2026-10-05 | pending |
| N-Formylmethionine | psoriatic arthritis | 0.451 | — | — | 2026-10-05 | pending |
| Artenimol | esophageal cancer | 0.451 | — | — | 2026-10-05 | pending |
| (3AR,6R,6AS)-6-((S)-((S)-CYCLOHEX-2-ENYL)(HYDROXY)METHYL)-6A-METHYL-4-OXO-HEXAHYDRO-2H-FURO[3,2-C]PYRROLE-6-CARBALDEHYDE | osteoporosis | 0.449 | — | — | 2026-10-05 | pending |